Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycinamide is a small, water-soluble organic compound that is the amide derivative of the amino acid glycine. It serves as a crucial intermediate in the de novo purine biosynthesis pathway, where it is converted into glycineamide ribonucleotide. Beyond its metabolic role, Glycinamide has been investigated for its potential therapeutic applications, particularly as a pro-drug for glycine. Upon metabolic conversion to glycine in the brain, it can exert analgesic effects by acting as an inhibitory neurotransmitter through glycine receptors and as a co-agonist at NMDA receptors. Additionally, Glycinamide has been shown to inhibit the conversion of proparathyroid hormone to parathyroid hormone. Its hydrochloride salt is also utilized as a buffering agent in cell culture and as a chemical intermediate in the synthesis of various medicinal compounds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glycinamide.